

<b>DATE:</b>	8 July 2024
<b>TO:</b>	Physicians and Nursing Staff, All Zones
<b>FROM:</b>	APL Transfusion Medicine
<b>RE:</b>	<b>Updates to Transfusion Medicine Client Resources</b>

---

**PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE**

---

**Key Message**

- New and revised Transfusion Medicine resources are available on [www.ahs.ca/labtransfusion](http://www.ahs.ca/labtransfusion).
- These resources provide information to support safe and appropriate transfusion practice in alignment with the [AHS Transfusion of Blood Components and Blood Products Policy](#)

**Background**

- Blood Component & Product Information / Monographs provide specific information required for obtaining, preparing, and transfusing blood components and products available in Alberta hospitals.

**Action Required**

- Review the most current version of the applicable Blood Component or Product Information / Monograph before transfusion.
- Review the new resources for changes that impact your zones.

Document	Rev #	Rev Date	Notes
<b>Revised Resources</b>			
<a href="#">Red Blood Cells Selection Policy</a>	4.01	Feb 2024	Major revision. <ul style="list-style-type: none"> <li>• K neg RBC no longer required for males of any age.</li> <li>• Clarification of neonatal needs.</li> <li>• Clarified for the transfusion requirements of patients with multiple antibodies</li> </ul>
	4.02	May 2024	Minor revision. Table 1. Stable Non-Bleeding Patient Transfusion Recommendations: <ul style="list-style-type: none"> <li>• Clarified scenarios for when HGB is &lt;60 and 60-70.</li> <li>• Added note for pediatric patients not requiring screening.</li> </ul> Table 5. Pretransfusion Testing for Special Clinical Indications: <ul style="list-style-type: none"> <li>• Removed Hereditary Spherocytosis</li> </ul> Table 6. RBC Selection for Special Clinical Indications: <ul style="list-style-type: none"> <li>• Immunotherapy section: Added requirement for full phenotype matched units when DTT treated cells have not been used to screen for underlying antibodies in patients that have been transfused.</li> </ul> Fixed typo in Background section. Updated hyperlinks.
<a href="http://albertahealthservices.ca">Platelet Selection Policy (albertahealthservices.ca)</a>	1.00	March 2024	New. Provides direction on determining the appropriateness of an order for platelets for the purpose of screening, preparing, and selecting the most appropriate unit.



Document	Rev #	Rev Date	Notes
<a href="#">Plasma Selection Policy (albertahealthservices.ca)</a>	2.00	Feb 2024	New to resource page. Provides direction on determining the appropriateness of an order for plasma for the purpose of screening, preparing, and selecting the most appropriate unit.
<a href="#">Irradiated Blood Products Policy</a>	5.21	March 2024	Major revision. <ul style="list-style-type: none"> <li>• Addition of irradiation equivalent information.</li> <li>• Removal of directed donation wording.</li> <li>• Removal of cryoprecipitate wording.</li> <li>• Clarification on the recommended durations for Fetus and Neonates with previous IUTs.</li> <li>• Updated recommended durations and additional information added according to the new NAC recommendations for guidance, including criteria for discontinuation of irradiation requirements.</li> </ul>
<a href="#">Prescriber Information - Perioperative Autologous and Directed Donations</a>	2.00	April 2024	Major revision. Changes related to the discontinuation of the Directed Donation program at Canadian Blood Services (CBS). Additional information added regarding the CBS Rare Blood and Specialized Cell Program. Renamed to reflect that autologous donations are perioperative.
<a href="#">IVIIG Infusion Rate Table - Adult</a>	2.11	May 2024	Minor revision. Added greater than/equal to 100 kg to table.
<b>New or Revised Blood Component Monographs</b>			
<a href="#">Glassia</a>	1.00	April 2024	New. Product monograph for Glassia, an alpha-1 proteinase inhibitor
<a href="#">HyQvia</a>	1.00	April 2024	New. Product monograph for HyQvia, a subcutaneous immune globulin (SCIG) with hyaluronidase. .
<a href="#">Granulocytes</a>	2.00	May 2024	Major revision. Annual review. <ul style="list-style-type: none"> <li>• Added pretransfusion and compatibility sections.</li> <li>• Added additional warning regarding pending transmissible disease testing.</li> <li>• Clarified typical transfusion frequency including pediatric.</li> <li>• Updated references.</li> </ul>
<b>Obsolete / Archived Documents</b>			
N/A	N/A	N/A	N/A

**Questions/Concerns**

- APL Transfusion Safety Team - [Transfusion.SafetyTeam@aplabs.ca](mailto:Transfusion.SafetyTeam@aplabs.ca)

**Approved by**

- Dr. Ghazal Radwi, TM Medical Lead North Zone, APL Transfusion and Transplantation Medicine Program

*Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.*